{
    "Enteropathogenic Esch. Coli Gastroenteritis In Premature Infants And Children Treated With Fosfomycin": "F.BAQUERO,T.CANEDO,A.RODRIGUEZ,andE.JASOClinicaInfantil'LaPaz',DepartamentodePediatriaandServiciodeMicrobiologiadelaC.S.'LaPaz',UniversidadAutonomadeMadrid;andInstitutodeFarmacologiaEspanola,MadridBaquero,F.,Caniedo,T.,Rodriguez,A.,andJaso,E.(1975).ArchivesofDiseaseinChildhood,50,367.EnteropathogenicEsch.eoligastroenteritisinprematureinfantsandchildrentreatedwithfosfomycin.Fortytwoinfants,somepremature,withenteropathogenicEsch.coli(EPEC)gastroenteritisweretreatedwithanoralsuspensionoffosfomycininadoseof100and200mg/kgperday.Afterthetreatmenttherewere11secondaryclinicalinfections(6reinfectionsand5relapses)whichreceivedasecondtreatmentwithfosfomycin.Intotal,53treatmentsweremadewithfosfomycinandin92%ofthecasestherewasbothclinicalandbacteriologicalcure.93%oftheEPECstrainsweresensitivetofosfomycininvitro,theirminimuminhibitoryconcentrationsbeing<64[\u00b1g/ml.Theconcentrationoffosfomycininbloodandfaeceswasassayedbyadiffusionplatemicrobiologicalmethodinagroupofthesechildren,showingthatthisantibioticispartlyabsorbedandtheresteliminatedinthefaeces,whereitsconcentrationwasfoundtobeveryhigh.Toleranceoftheproductwasgood,andtherewereneithertoxicnorsideeffects.FosfomycinisanewwidespectrumantibioticdescribedbyHendlinetal.(1969)andStapleyetal.(1970).ItisveryactiveinvitroagainstEsch.coli(Zimmermanetal.,1970;KestleandKirby,1970;Martinetal.,1970;MorenoLopezetal.,1971)andhaspracticallynotoxicity(Milleretal.,1970).Theabsorptionofanoraldoseinmanisapproximately30to40%(RodriguezandMata,19681969;Foltz,Wallick,andRosenblum,1970).TheabsenceoftoxicityandthehighacitivityagainstEsch.colimadeustrythisnewantibioticonagroupof39prematurebabiesandinfantswithgastroenteritisand3carriersofenteropathogenicEsch.coli(EPEC).",
    "Material And Methods": "Patients.TableIshowstheageandsexofthe42childrenstudied.90%werelessthan3monthsoldand40%werepremature.39ofthemhaddiarrhoeawithtwopreviousstoolculturespositiveforEPEC.Itisimportanttoemphasizethat76%ofthechildrenwereinfectedwithEPECinhospital.Thestudywasmadeduringahospitalepidemiccausedbythe0126:K71B16serotype;forthisserotypetheproportionofchildrenReceived7October1974.infectedinhospitalwas94%.In36childrentherewereotherdisordersaslistedinTableII.TableIIIshowsthetreatmentsusedbeforefosfomycin.In32children(79%)anantibiotichadbeenusedandin19ofthesethetreatmentlastedmorethanaweekwithoutobtaininganyclinicalorbacteriologicalimprovement.Treatmentanddosage.Thefosfomycincalciumsaltwasusedasasuspensioncontaining50mg/mlofactiveproduct.Itwasgivenorallyastheonlyantibiotic,indosesof100or200mg/kgperdaydividedinto3or4unitsforanaverageof7days.Bacteriologicalstudy.Theselectionanddiagnosisofallthecasesweremadebystoolcultureandimmunofluorescence.Thefollowingculturemediawereused:MacConkeyagar,Selenitebroth,SSagar,MRSagar,Mycobioticagar,andMannitolSaltagar.Colonycountsweremadeonfreshspecimensoffaeces,whichwerehomogenizedandthendiluted1/10to1/10000;005mlofeachdilutionwereplatedoutonCysteineLactoseElectrolyteDeficientagar(Oxoid).Thedirectimmunofluorescenceexaminationwasmadeonthe1/10dilutionofthefaecesusingpolyvalentantiseraconjugatedtofluoresceinisothiocyanate,contraststainedbyrhodamine.EPECserotypingwasdonewithantiserausingthe367",
    "Baquero, Ca-Nedo, Rodriguez, And Jaso Table I": "|Clinicalstates|Primarycases|Secondarycases||||||Serious|18|||Mild|21|11||Carriers|3|||Numbersinparenthesesindicateprematures.|||",
    "Table Ii": "Concomitantstates|DigestiveapparatusIntestinalmalrotation2;postoperativeomphalocele1;oesophagealatresia1;analatresia1;megacolon1;malabsorptiondystrophy2Circulatoryrespiratoryapparatus|5|||||Pre/postoperativecardiopathywith/withouthepatomegaly3;pulmonaryagenesis1;transpositionofmainarteries1|||Infections|13||Bronchopneumonia3;otitis5;pharyngealcarriersofPseudomonas2;bacteriuriabyEPECandEnterobacter1;hepatitis1;sepsisbyEsch.coli1;|||Nervoussystem|1||Cerebralpostanoxicparalysis1|||Others|9||Mongolism1;hypocalcaemia1;rickets3;antiDisoimmunization1;transfusionreaction1;hydrocele2||",
    "Table Iii": "Previousantibiotictreatmentsin42patients|No.(%)||||||||Nopreviousantibiotictreatment|3|(71)||Antibiotictreatmentunrelatedtogastroenteritis|6(143)|||Previoustreatmentforgastroenteritis|32(78*6)|||NatureofprevioustreatmentColistinalone|12|||Colistinandnifuroxazide|11|||Nifuroxazideandnalidixicacid|5|||Sulphonamidesneomycin|4||methodofthePasteurInstitute(LeMinor,1972).PolyvalentOBandspecificOB/Oantiserawereused;forthelatter,theminimumagglutinatingvalueswere1:200forthe0titreand1:1600fortheBtitre.Theantibioticsensitivityofthestrainstofosfomycin,otherantibioticandchemotherapeuticagents,wasexaminedbythediscplatetest.Theminimuminhibitoryconcentrations(MIC)ofeachstraintofosfomycinwasdeterminedbytheagardilutionmethodusingtechniquesrecommendedbyWHO(EricssonandSherris,1971).Aninhibitionzoneof10mmrounda30,ugdiscwasconsideredtobetheminimumreflectingatherapeuticresponsetotheantibiotic.Thecriteriarecommendedbythesuppliers(PasteurInstitute)werefollowedfortheotherantibiotics.Bacteriologicalexaminationofthefaeceswasrepeatedevery3daysduringthecourseoftreatment,3daysafterendingit,andafterwardsbetweenthefirstandfourthweeks.Fosfomycindeterminations.DeterminationsoffosfomycininbloodandfaecesweremadeusingaplatediffusionmicrobiologicalmethodwithMB1159Erwiniaatrosepticaasthetestorganism(H.WallickandW.Maiese,personalcommunication,1969).Concentrationsforthestandardcurvewere0*5,075,10,1*5,and2*0,ug/ml,anddilutionsweremadeinhumanserumorpH8*0Trisbuffer(0*05mol/l)dependingupontheassay.Serumsamplesweredilutedinhumanserumandstoolsamplesinbuffertoapproximately10,ug/ml.Attheworkingdilutionsnostoolbacterialinterferencewasseeninthedeterminations.Evaluationcriteriaandsecondaryinfections.Wecallmildcasesthosewhichdonotrequireintravenousfluidsandseriouscasesthoseneedingintravenousdripsandfrequentlyhavingelectrolytedisturbances.Thecriteriaofcurewerebasedonthefollowingparameters:theremissionofdiarrhoea,recoveryoflostweight,andeliminationofEPECfromfaeces.WhenEPECwereeliminatedwithoutclinicalresponse,therewassaidtobeabacteriologicalcure.Afailurewasrecordedwhentherewasneitheraclinicalnorabacteriologicalcure.ReinfectionswereconsideredtobethosecasesinwhichadifferentserotypeorantibiotypeofEPECwas",
    "368 Enteropathogenic Esch. Coh Gastroenteritis In Premature Infants And Children Table Iv 369": "|Primarycases|Secondarycases|||||||||||Serotypes||Total(%)||||1Typeonlyisolated|2Typesisolated|1Typeonlyisolated||||018:K21B75||2|2(3)|||055:K59B5|1||1|2(3)||0111:K58B4|12||2|14(25)||0119:K69B14|4||1|5(9)||0125:K70B15|2|4||6(11)||0126:K71B16|19|4|5|28(49)||Totalstrains|38|8|11|57(100)||38|4|11||||(905%)|(95%)|||||Totalcases|42|11|[|53|found.WhentheEPECinthefaeceshadthesamefaecalis,andnonserotypedEsch.coli(TableV).serotypeandantibiotype,thenitwasconsideredtobeThesensitivityofthe57EPECstrainsfoundatrelapse.thebeginningofthetreatmenttofosfomycinandResultsotherantibioticsandchemotherapyagentsisMicrobiologicalstudy.AllthestoolculturessummarizedinTableVI.GentamicinandfosoftreatedchildrengrewEPEC.In4casestherefomycinarethemostactiveagents.IntheFig.wasamixedinfectionwithtwodifferentserotypes.itcanbeseenthatallthefosfomycinsensitiveThe57EPECstrainsfoundweredistributed(TableIV)throughout6differentserotypes,the%/omostfrequentbeing0126:K71B16(49%)and0111:7\u00b06L_oK58B4(25%).Thequantitativestoolculturesandthedirect80immunofluorescencegavecongruentresults.In4theprimaryinfectionstheaverageparticipation60\u00b0colonycountofEPECinrelationtothetotalcountofaerobicbacterialflorawas76%,including4014casesinwhichEPECinpureculturewasisolated.TheEPECcountvariedbetween108and201010colonies/gfaeces.Inthesecondaryinfections,1.however,theparticipationofEPECinrelationtousceptiblestrains__.Resistontstrainsthetotalaerobicbacterialflorawassmaller(41%u/mi816326428256(mm)zoneofinhibilon302520Is10average),thecountsalsobeinglowerthaninthestrainsnumber10I)3034primaryinfections.In66%ofthestoolculturesFIG.Cumulativepercentagesofthevaluesofminimalmadebeforetreatment,inadditiontoEPEC,thereinhibitoryconcentrationsofstrainsofEPECisolated,andweresmallnumbersofEnterobacter,Streptococcuscorrelationwiththediameterofthezoneofinhibition.![2__0.](2__0.)|Organism|Before|34thdayof|3daysafter|||||||treatment(%|treatmnent(%|treatment(%|||Esch.colinonserotyped|11*3|52*1|67*3||Enterobactercloacae|528|667|710||Streptococcusfaecalis|340|313|232||Note:Thepercentagesinthistablecorrespondtothecasesfromwhosestoolstheindicatedorganismswereisolated.||||",
    "Baquero, Ca-Nedo, Rodriguez, And Jaso Table Vi": "Susceptibilityof57strainsofEPECisolatedfrom42primarycasesand11secondarycases|Antibioticor|Concentrationof|%ofsusceptible||||||chemotherapeutic|disc(,g)|strains||Gentamicin|30|100||Fosfomycin|30|93*0||Nitrofurantoin|300|881||Colistin|10|697*||Nalidixicacid|30|571||Cephalothin|30|52*4||Tetracycline|30|21*4||Novobiocin|30|143||Erythromycin|15|9.5||Neomycin|30|440||Streptomycin|30|2*4||Kanamycin|30|24||Carbenicillin|100|0||Ampicillin|25|0||Chloramphenicol|30|0||Sulphonamides|50|0||*Ordinarilythepercentagesusceptibilitytocolistinofthe|||*OrdinarilythepercentagesusceptibilityEPECstrainsisgreaterthanthisintheclinic.tocolistinofthestrainshadanMICof64[\u00b1g/mlorless,withaninhibitionzonediameterbiggerthan10mm;onlythe4strainsresistantto30,ugfosfomycindiscexceededthisvalue.ThesewerestrainsofEsch.colitype0111:K58B4andinspiteoftheircomparativeinvitroresistance,theywereeliminatedfromthefaeceswiththesameeaseasthesensitivestrains,probablybecausetheconcentrationsofactivefosfomycinintheintestinaltractweremuchgreaterthantheMICvaluesofthestrains.Inallcases,primaryandsecondary,oraladministrationoffosfomycinwasfollowedbytheeliminationofEPECfromthefaeceswithin3daysoftreatment.Secondaryinfectionsappeared2weeksafterstoppingtreatmentandthenonlyinchildrenwhoforotherreasonshadstayedinhospital,EPECbeingfoundagaininthestoolculturesof11children.Accordingtoourcriteria,outofthe11secondaryinfectionsweconsidered6tohavereinfections(14%)and5relapses(12%).Allcasesdevelopedmilddiarrhoea.Bacteriologicalstudiesshowed(TableV)thattheactionoffosfomycinwasspecificagainstthecausalmicroorganism(EPEC)withoutappreciablyalteringtherestofthebacterialflora.ItisdifficulttoexplainwhynonpathogenicEsch.coliwereselectedduringthefosfomycintreatment.TheselectionofE.cloacaecouldbebasedonthefrequentresistanceofthisspeciestofosfomycin.Fosfomycinbloodandfaecalconcentrations.TableVIIAshowstheresultsofbloodlevelsintwogroupsofchildrentreatedwithdosesoffosfomycinof100and200mg/kgperday.Thoughafterthefirstdosethegroupofchildrentreatedwiththesmallerdosehadanaveragebloodlevellowerthanthesecondgrouptreatedwithtwicethedose,afterafewdaysoftreatmentthefirstgroup,whowereallprematurebabies,showedlevelsmuchhigherthan|Averagebloodlevels(,ug/ml)||||||||||||Treatmentanddosage|Afterthe1stdose(h)|Duringtreatmenton||||1|2|6|3rdto7thd:Ih|||11patients(8prematures)100mg/kgperdayindosesof25mg/kg|28|29|27|142||SD|(0*6)|0*7)|(0*9)|(2*3)||12patients200mg/kgperdayindosesof50mg/kg|46|43|3*4|7*8||SD|(1*6)|(0*5)|(0*4)|(0*9)|(B)Fosfomycinconcentrationinfaeces|Treatmentanddosage|Averageof11caseson34thdoftreatment|||||11patients|37ztg/g,faecesjusteliminated(maximumvalue855Ztg/g;minimumvalue||200mg/kgperdayindosesof50mg/kg|133ztg/g)||SD,standarddeviation.||",
    "370 Enteropathogenic Esch. Coh Gastroenteritis In Premature Infants And Children": "|Primarycases(and%)|Secondarycases(and%)|Total||||||||(18serious,21mild,|(allmild;6reinfect||||and3carriers)|ionsand5relapses)|(|||Patientstreated|42(100)|11(100)|53(100)||Bacteriologicalcures|42(100)|11(100)|53(100)||Clinicalcures|38*(904)|11(100)|49(924)||*The4remainingcasesweregivensuccessfulcorrectivedietetictreatmentforsymptomsofmalabsorption.||||thoseofthesecondgroup,nodoubtduetotheaccumulationoffosfomycinduetothephysiologicalrenalinsufficiencyinprematurechildren.Inanothergroupof11children,treatedwith200mg/kgperdaygivenin4doses(TableVIIB)theconcentrationoffosfomycininfaeceswasdetermined.Itwasnotintendedtostudyquantitativelyeliminationthroughtherectalroute,buttodeterminetheactiveantibioticconcentration.Clinicalresults.TableVIIIsummarizestheresultsoffosfomycintreatmentof42patientswhoreceivedatotalof53treatments.ThoughEPECwasalwayseliminatedquickly,in4casesdiarrhoeaonlyceasedafteradequatedietarytreatment.The11secondaryinfectionsallrespondedwelltoasecondcourseoffosfomycin,withnoappreciabledevelopmentofEPECresistancetoit:inonecaseEPECMICincreasedfrom8to64jig/ml.Clinicalprogresswasexcellentinallpatients,exceptforthe4mentionedabove,andthegeneralconditionimprovedrapidly,evenintheseriouslyillpatients.Thestoolsbecamenormalinnatureandfrequencyafterthethirddayoftreatment.Excludingthe3carriers,theaveragenumberofstoolsfellfrom7perdaybeforetreatmentto3perdayafter.Weight,whichwasdecreasingorstaticbeforetreatment,increasedgraduallyasthechildrenimprovedanddiarrhoeastopped.Theaverageincreasewas74%attheendoftreatment,and134%forthe17prematurechildren.Fosfomycinwasshowntobemoreactiveinvivothaninvitro,sincethe4EPECinitiallyresistantwerealsoeliminated,owingnodoubttothehighfosfomycinconcentrationsobtainedinsitu,farexceedingtheMICofthesemicroorganisms.Theresultsdidnotappeartodifferaccordingtothedosageused(100or200mg/kgperday).Toleranceandtoxicity.Therewerenosideeffects,superinfections,orcandidiasis,andnoevidenceoftoxicityfromthebloodanalysisdata.Transaminaselevelsdidnotchangewithfosfomycin4treatment,sincetheaverageSGOTvaluesbefore,during,andaftertreatmentwere46,47,and49ReitmanFrankelunitsandSGPT31,36,and30ReitmanFrankelunits.Innocasedidwefindanyincreaseinthevaluesoftransaminase,urea,creatinine,andalkalinephosphatase.",
    "Discussion": "ThetreatmentofintestinalbacterialinfectionswithantibioticswasquestionedbyDixon(1965)andAserkoffandBennett(1969),whonotedalongerperiodofexcretionofthepathogenicflorainthetreatedpatientsthaninnontreatedones.Technicalprogressinfluidreplacementandinthegeneralcareofthechildwithdiarrhoeahaveconsiderablyimprovedtheprognosisofthesepatients,butwebelievethatantibiotictherapycanimproveitfurther,especiallyintheacutephaseofthedisease.IntheintestinalinvasivegrowthphaseofEPEC,antibioticscanprobablyreducethepathogenicEPECpopulationandsothetotalamountofenterotoxinproduced,decreasingthepathophysiologicaleffectsofthissubstance.Also,asthepathogenicEPECpopulationisreducedinthebaby,antibiotictherapycouldhelppreventacuteepidemicdissemination,whichisveryimportantinchildren'shospitals.Itispossiblethatthewidespectrumantibiotics,especiallyhighdoses,causesuppressionofthenormalantagonistflorapermittingapossiblesuperinfection,relapse,orreinfection.Thepossibilityofaffectingthenormalantagonistfloraisprobablymoreimportantinthesubacuteorchronicphaseofthediseasecorrespondingtothespontaneousresettlementofthisflora.Thiscouldexplainthenegativeeffectoftheprolongedantibiotherapyintheproportionofcarriersofenteropathogenicorganismsaftertheacutebacterialdiarrhoea.Haltalin,Nelson,andKusmiesz(1973)haveshownthenecessityofusingabsorbableantibioticsinthetreatmentofshigellosis,andthesamemaybetrueforsomeEPECgastroenteritis.Becausefosfomycinisabsorbeditprovidestherapeuticserumlevelsandahighintraluminalcon",
    "372 Baquero, Cafnedo, Rodriguez, And Jaso": "centrationinactiveform.Withthedoseused,iteliminatesEPECrapidlyfromthestoolwithoutappreciablyalteringthenormalentericflora.TheEPECstrainsfoundweresensitivetofosfomycinandnoappreciableEPECresistancedevelopedinthe53treatments.Hendlinetal.(1970)showedthatthedevelopmentofresistancetofosfomycininvitroisofachromosomalnatureandthattheresistantstrainsaredefectivemetabolicmutantsthatlosetheoriginalvirulenceofthepathogenicstrains:theycannottransferinvitrotheirbacterialresistancetofosfomycin,indicatingthatthisisnotofaplasmidicnature.Thisantibioticwaswellacceptedandtoleratedbychildrenandnotoxicitywasdetected.FosfomycincanbeconsideredtobeavaluableantibioticforthetreatmentandepidemiologicalcontrolofEPECinfectionsinhopitalizedchildren.REFERENCESAserkoff,B.,andBennett,J.V.(1969).EffectofantibiotictherapyinacutesalmonellosisonthefecalexcretionofSalmonellae.NewEnglandjournalofMedicine,281,636.Dixon,J.M.S.(1965).EffectofantibiotictreatmentondurationofexcretionofSalmonellatyphimuriumbychildren.BritishMedicalJournal,2,1343.Ericsson,H.M.,andSherris,J.C.(1971).Antibioticsensitivitytesting.ActaPathologicaetMicrobiologicaScandinavica,Sect.B.,Suppl.217.Foltz,E.L.,Wallick,H.,andRosenblum,C.(1970).Pharmacodynamicsofphosphonomycinafteroraladministrationinman.AntimicrobialAgentsandChemotherapy,1969,p.322.Ed.byG.L.Hobby.AmericanSocietyofMicrobiology,Bethesda,Maryland.Haltalin,K.C.,Nelson,J.D.,andKusmiesz,H.T.(1973).Comparativeefficacyofnalidixicacidandampicillinforsevereshigellosis.ArchivesofDiseaseinChildhood,48,305.Hendlin,D.,Stapley,E.O.,Jackson,M.,Wallick,H.,Miller,A.K.,Wolf,F.J.,Miller,T.W.,Chaiet,L.,Kahan,F.M.,Foltz,E.L.,Woodruff,H.B.,Mata,J.M.,Hernandez,S.,andMochales,S.(1969).Phosphonomycin:anewantibioticproducedbystrainsofStreptomyces.Science,166,122.Hendlin,D.,Frost,B.M.,Thiele,E.,Kropp,H.,Valiant,M.E.,Pelak,B.,Weissberger,B.,Comin,C.,andMiller,A.K.(1970).Phosphonomycin:evaluationinvitro.AntimicrobialAgentsandChemotherapy,1969,p.297.Ed.byG.L.Hobby.AmericanSocietyforMicrobiology,Bethesda,Maryland.Kestle,D.G.,andKirby,W.M.M.(1970).Clinicalpharmacologyandinvitroactivityofphosphonomycin.AntimicrobialAgentsandChemotherapy,1969,p.332.Ed.byG.L.Hobby.AmericanSocietyforMicrobiology,Bethesda,Maryland.LeMinor,L.(1972).Lediagnosticdelaboratoiredesbacillesagramnegatif.Enterobacteries,4thed.,p.99.Ed.bydelaTourelle.Martin,I.,Mochales,S.,Hernandez,S.,Rodriguez,A.,andMata,J.M.(1970).Estudiosdesensibilidadbacterianafrentealafosfonomicina.AnalesdelInstitutodeFarmacologiaEspafiola,19,327.Miller,A.K.,Frost,B.M.,Valiant,M.E.,Kropp,H.,andHendlin,D.(1970).Phosphonomycin:evaluationinmice.AntimicrobialAgentsandChemotherapy,1969,p.310.Ed.byG.L.Hobby.AmericanSocietyforMicrobiology,Bethesda,Maryland.MorenoLopez,M.,Damaso,D.,Perea,E.J.,Sousa,A.S.,Martinez.,M.L.,andMarco,M.L.(1971).Phosphonomycin:quantitativesensitivityspectraofvarioushospitalstrainstothisnewantibiotic.MicrobiologiaEspaniola,24,79.Rodriguez,A.,andMata,J.M.(19681969).Datosfarmacodinamicossobrelaadministraci6ndelafosfonomicinaenelhombreporlasviasintramuscularyoral.AnalesdelInstitutodeFarmacologia,1718,439.Stapley,E.O.,Hendlin,D.,Mata,J.M.,Jackson,M.,Wallick,H.,Hernandez,S.,Mochales,S.,Currie,S.A.,andMiller,R.M.(1970).Phosphonomycin:I.Discoveryandinvitrobiologicalcharacterization.AntimicrobialAgentsandChemotherapy,1969,p.284.Ed.byG.L.Hobby.AmericanSocietyforMicrobiology,Bethesda.Maryland.Zimmerman,S.B.,Stapley,E.O.,Wallick,H.,andBaldwin,R.(1970).Phosphonomycin:susceptibilitytestingmethodandsurvey.AntimicrobialAgentsandChemotherapy,1969,p.303.Ed.byG.L.Hobby.AmericanSocietyforMicrobiology,Bethesda,Maryland.CorrespondencetoDr.F.Baquero.Ardemans623',Madrid28,Spain.![6__0.](6__0.)fosfomycin.infantsandchildrentreatedwith",
    "Gastroenteritis In Premature Enteropathogenic Esch. Coli": "FBaquero,ECanedo,ARODRIGUEZandEJasodoi:10.1136/adc.50.5.367ArchDisChild197550:367372|Updatedinformationandservicescanbefoundat:http://adc.bmj.com/content/50/5/367Theseinclude:||||||Emailalertingservice|Receivefreeemailalertswhennewarticlescitethisarticle.Signupintheboxatthetoprightcorneroftheonlinearticle.|Noteshttp://group.bmj.com/group/rightslicensing/permissionsTorequestpermissionsgoto:http://journals.bmj.com/cgi/reprintformToorderreprintsgoto:http://group.bmj.com/subscribe/TosubscribetoBMJgoto:"
}